For Sarah Bowen, it all started with a sore throat. Not the kind of searing pain shed feel with strep, she said, but a throat irritation that just didnt feel right.
By the end of the day, it just got a little worse and I didnt feel great. I felt like I might be coming down with something. And the next day, things got worse, Bowen, 31, of Portland, Oregon, said.
Full coverage of the coronavirus outbreak
Bowen works at a doctors office, where she was immediately able to get tested for COVID-19, on May 8. It came back negative, and her doctor said the symptoms were most likely allergies or another virus.
But from there, things snowballed. Bowen developed headaches, a stuffy nose, hot flash symptoms and constant headaches. By day six, she felt like she was hit by a truck. She had extreme fatigue and a burning sensation in her chest.
I started getting shortness of breath if I went upstairs to get water or something, Bowen said. It got worse when I moved around.
Two days later, she took another test for COVID. Again, it came back negative.
But despite her symptoms, her doctor didnt believe she had the virus, because there werent many cases in the Portland suburb where she lives. Frustrated, Bowen continued to isolate alone in the downstairs of her home. She didnt want to take any chances.
Its one thing to get sick and know its a cold or the flu. But to get sick during a pandemic and to be kind of dismissed, makes you feel crazy, she said.
Bowens diagnosis remains unclear, but her experience raises questions about the accuracy of diagnostic tests for the disease. Indeed, as more and more people have access to testing, new data show that false negatives on COVID-19 tests may be more common than first realized.
And as the U.S. starts to reopen, accurate testing is one of the most important tools in states' arsenals to track and stop the spread of the coronavirus.
Since the pandemic started spreading across the United States in March, nearly 70 tests have received emergency use authorization from the Food and Drug Administration. Many of these tests were developed at a breakneck pace in an effort to get tests out to the American people.
But while no test is perfect, experts told NBC News that these particular tests used to diagnose COVID-19 may be missing up to 20 percent of positive cases.
One key reason behind these so-called false negatives may be how the testing samples are collected.
The false negatives are mainly due to specimen acquisition, not the testing per se, said Dr. Alan Wells, medical director for the University of Pittsburgh Medical Center clinical laboratories and a professor of pathology at the University of Pittsburgh.
Most tests use a method called polymerase chain reaction or PCR. It detects coronavirus genetic material thats present when the virus is active. Clinicians typically collect a sample for testing from the back of a persons throat where the virus is presumed to be with a long nasopharyngeal swab.
Download the NBC News app for full coverage of the coronavirus outbreak
Let our news meet your inbox. The news and stories that matters, delivered weekday mornings.
But scientists say that collection method is ripe for error.
Youre sampling blindly. Youre hoping you get the right spot. Then as the disease progresses, the virus might migrate down into your lungs, Wells said, adding that once its in the lungs, that nasopharyngeal swab may not pick up any virus if its already been cleared from the throat.
You have to be at the right place at the right time, he said.
Another type of diagnostic test forgoes the uncomfortable swab altogether, and instead uses saliva collected in a test tube. Once the sample arrives in the lab, its tested the same way, with PCR.
But Wells said those tests could fare even worse.
The reason for pharyngeal swabs is the virus preferentially infects and replicates starting way back in the inner cavities of the nose and not out in front, where it may come into contact with saliva, he said, adding that saliva tests could end up missing up to 50 percent of asymptomatic positive cases.
Making things even more complicated, a May 13 study in Annals of Internal Medicine, from researchers at the Johns Hopkins Bloomberg School of Public Health in Baltimore, found that test timing is also essential to getting an accurate result.
Lead study author Dr. Lauren Kucirka, a medical resident at Johns Hopkins Medicine, said testing too early after exposure to the virus substantially raises the risk of a false negative.
If you have someone who has been exposed and theyve started to develop symptoms, it probably makes sense to wait a few days before testing, Kucirka told NBC News.
Her study found that three days after the onset of symptoms is when the test is most likely valid.
But besides issues with how and when test samples are collected, questions are also being raised about the quality of the diagnostic tests themselves.
The biggest problem with that is you create a false sense of security.
In other words, even if samples are collected perfectly, at the ideal time, the tests could turn up incorrect results. A commentary published in April in Mayo Clinic Proceedings criticized the reliance on PCR tests, saying that even when tests are 90 percent accurate, that still leaves a substantial number of false test results.
The articles co-author, Dr. Priya Sampathkumar, an infectious disease specialist at the Mayo Clinic, used California as an example in a statement: If the entire population of 40 million people were tested, there would be 2 million false negative results. Even if only 1 percent of the population was tested, there would be 20,000 false negatives.
The biggest problem with that is you create a false sense of security, Wells said.
Another type of COVID-19 diagnostic test, Abbott Labs popular ID NOW point-of-care test, has also come under fire in recent weeks, after the FDA issued an alert that it may not always be accurate.
The test, which uses a method different from PCR, called isothermal nucleic acid amplification, can deliver results in five to 13 minutes. Its used by doctors across the country and touted by the White House as whats used to test President Donald Trump and other staffers.
One small study by NYU Langone Health found that the test returned false negatives for nearly 50 percent of certain samples that a rival test had found to be positive. The study has not yet been peer-reviewed.
In response, Abbott last week released interim data on several of its own studiesfinding that accuracy was significantly better, in some cases nearly 100 percent, especially when performed in patients who were tested early after their onset of symptoms.
But anecdotal reports have also found issues with accuracy, leading some of the nations largest medical centers to stop or never even start using it.
NBC News spoke with 10 medical centers and hospitals across the country; seven said they werent using the Abbott test.
All seven cited issues with accuracy, including Jackson Memorial Hospital System in Miami, which said in a statement that they identified some issues with the accuracy, which is to be expected when the medical science is so new and evolving so quickly around this virus. The best fit for Jackson was to transition to other testing platforms that have high-quality accuracy rates and quick turnaround times for results.
A Vanderbilt University Medical Center spokesman told NBC News that No patient at Vanderbilt University Medical Center has been tested via the Abbott ID NOW rapid test. Here, there were concerns about the sensitivity of that test.
Some hospitals continuing to use the Abbott test, such as Sutter Health Hospitals in California, said they often will confirm any negative results with another PCR test if there is clinical suspicion of COVID-19.
Abbott told NBC News in a statement that to date, the company has delivered more than 2 million tests to all 50 states.
"Our customers are telling us that theyre seeing positivity rates from ID NOW testing at or above local community infection rates, which means that ID NOW is detecting the virus at the same level as lab-based testing," the statement said in part. "If there were any systemic problem with ID NOW producing false negatives, that wouldnt be the case."
The bigger issue may be that test manufacturers just havent caught up to science. Its not just COVID-19 tests that have issues with accuracy. In fact, diagnostic tests for all sorts of common diseases are not even close to perfect.
Take rapid strep throat tests, for instance. According to a Cochrane Review, those tests have a sensitivity of just 86 percent. The Centers for Disease Control and Prevention says rapid flu tests are even worse, with a sensitivity ranging from 50 to 70 percent.
Rapid strep and rapid flu tests look for antigens proteins made by the infectious pathogen rather than genetic material. The first antigen test for COVID-19 received an emergency use authorization from the FDA earlier this month, but questions have already been raised about its accuracy.
Taken together, its why Dr. Ania Wajnberg, associate director of medicine at the Icahn School of Medicine at Mount Sinai, said that diagnostic tests need to be put together with clinical suspicion.
We still have a lot to learn, but testing itself is hugely important, Wajnberg said. If its not perfect, it doesnt mean its not useful.
Follow NBC HEALTH on Twitter & Facebook.
More:
Questions about COVID-19 test accuracy raised across the testing spectrum - NBC News
- Clemson professor Trudy Mackay elected to the National Academy of Medicine - Clemson News - October 22nd, 2024
- Research sheds new light on the behavior of KRAS gene in pancreatic and colorectal cancer - News-Medical.Net - October 22nd, 2024
- Pushing the boundaries of rare disease diagnostics with the help of the first Undiagnosed Hackathon - Nature.com - October 22nd, 2024
- Tailored Genetic Medicine: AAV Gene Therapy and mRNA Vaccines Redefine Healthcare's Future - Intelligent Living - October 22nd, 2024
- The Genetic Link to Parkinson's Disease - Hopkins Medicine - August 27th, 2022
- Epic Bio makes gene therapies by editing the epigenome - Labiotech.eu - August 27th, 2022
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 27th, 2022
- Whole-exome analysis of 177 pediatric patients with undiagnosed diseases | Scientific Reports - Nature.com - August 27th, 2022
- First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN (valoctocogene roxaparvovec), Approved by European Commission (EC) -... - August 27th, 2022
- Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases - BioSpace - August 27th, 2022
- ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines - Business Wire - August 27th, 2022
- ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene... - August 27th, 2022
- Genetic variants cause different reactions to psychedelic therapy - The Well : The Well - The Well - August 27th, 2022
- Personalized Medicine for Prostate Cancer: What It Is and How It Works - Healthline - August 27th, 2022
- Four radical new fertility treatments just a few years away from clinics - The Guardian - August 27th, 2022
- Why are Rats Used in Medical Research? - MedicalResearch.com - August 27th, 2022
- The Columns Stepping Stones in STEM Washington and Lee University - The Columns - August 27th, 2022
- Study points to new approach to clearing toxic waste from brain Washington University School of Medicine in St. Louis - Washington University School... - August 27th, 2022
- ALS Gene Therapy SynCav1 Found to Extend Survival in Mouse Model |... - ALS News Today - August 27th, 2022
- A New Kind of Chemo | The UCSB Current - The UCSB Current - August 27th, 2022
- Unraveling the mystery of who gets lung cancer and why - Genetic Literacy Project - June 16th, 2022
- How diet and the microbiome affect colorectal cancer - EurekAlert - June 16th, 2022
- Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear... - May 20th, 2022
- Money on the Move: SwanBio, Remix, Locus, Mirvie and More - BioSpace - May 20th, 2022
- DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients - PR Newswire - May 20th, 2022
- Brain tumor growth may be halted with breast cancer drug - Medical News Today - May 20th, 2022
- LogicBio Therapeutics to Present at HC Wainwright Global Investment Conference - PR Newswire - May 20th, 2022
- Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene... - May 20th, 2022
- Encoded Therapeutics Presents Nonclinical Data Showing Genomic Medicine Platform Yields Selective Expression to Optimize Gene Therapy Performance at... - May 20th, 2022
- California, Other States to Cover Rapid WGS of Newborns Under Medicaid, but Questions of Access Loom - GenomeWeb - May 20th, 2022
- Researchers Identify Role of 'Sonic the Hedgehog' Gene in Bone Repair - BioSpace - May 20th, 2022
- Targeting the Uneven Burden of Kidney Disease on Black Americans - The New York Times - May 20th, 2022
- ASC Therapeutics, U Mass Medical School, and the Clinic for Special Children Announce Podium Presentation of Safety and Efficacy in Murine and Bovine... - May 20th, 2022
- UC Davis Looks to Expand Genetic Breast Cancer Risk Education, Outreach for Hispanic Women - Precision Oncology News - May 20th, 2022
- Fly Researchers Find Another Layer to the Code of Life - Duke Today - May 20th, 2022
- CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business... - May 20th, 2022
- Omicron BA.4 and BA.5: What to know about the new variants - Medical News Today - May 20th, 2022
- Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting -... - May 20th, 2022
- FDA approves Lilly's Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2... - May 20th, 2022
- Elucidating the developmental origin of life-sustaining adrenal glands | Penn Today - Penn Today - May 20th, 2022
- 5 questions facing gene therapy in 2022 - BioPharma Dive - January 17th, 2022
- In a First, Man Receives a Heart From a Genetically Altered Pig - The New York Times - January 17th, 2022
- Antibodies, Easy Single-Cell, Genomics for All: Notes from the JP Morgan Healthcare Conference - Bio-IT World - January 17th, 2022
- Using genetics to conserve wildlife - Pursuit - January 17th, 2022
- Genetics of sudden unexplained death in children - National Institutes of Health - January 17th, 2022
- Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance - Yahoo Finance - January 17th, 2022
- Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically... - January 17th, 2022
- How The mRNA Vaccines Were Made: Halting Progress and Happy Accidents - The New York Times - January 17th, 2022
- Press Registration Is Now Open for the 2022 ACMG Annual Clinical Genetics Meeting - PRNewswire - January 17th, 2022
- A Novel Mutation in the TRPM4 Gene | RRCC - Dove Medical Press - January 17th, 2022
- Biomarkers and Candidate Therapeutic Drugs in Heart Failure | IJGM - Dove Medical Press - January 17th, 2022
- Genetic counseling program helps patients take control of their health - Medical University of South Carolina - June 24th, 2021
- One-year-old baby in UAE receives imported genetic medicine to treat rare disease - Gulf News - June 24th, 2021
- Black and non-Hispanic White Women Found to Have No Differences in Genetic Risk for Breast Cancer - Cancer Network - June 24th, 2021
- What's in your genes | The Crusader Newspaper Group - The Chicago Cusader - June 24th, 2021
- Immusoft Announces Formation of Scientific Advisory Board - Business Wire - June 24th, 2021
- Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress - Business... - June 24th, 2021
- Pacific Biosciences and Rady Children's Institute for Genomic Medicine Announce its First Research Collaboration for Whole - GlobeNewswire - June 24th, 2021
- Despite the challenges of COVID-19, Yale-PCCSM section members continued their work on scientific papers - Yale School of Medicine - June 24th, 2021
- Veritas Intercontinental: Genetics makes it possible to identify cardiovascular genetic risk and prevent cardiac accidents such as those that have... - June 24th, 2021
- New Research Uncovers How Cancers with Common Gene Mutation Develop Resistance to Targeted Drugs - Newswise - June 24th, 2021
- Celebrate the Third Annual Medical Genetics Awareness Week April 13-16, 2021 - PRNewswire - February 14th, 2021
- How will WNY fare in the race between vaccines and coronavirus variants? - Buffalo News - February 14th, 2021
- Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences - GlobeNewswire - February 14th, 2021
- ASCO GU 2021: The Landscape of Genetic Alterations Using ctDNA-based Comprehensive Genomic Profiling in Pat... - UroToday - February 14th, 2021
- The Human Genome and the Making of a Skeptical Biologist - Scientific American - February 14th, 2021
- Breast Cancer Gene Mutations Found in 30% of All Women - Medscape - February 1st, 2021
- Mysterious untreatable fevers once devastated whole families. This doctor discovered what caused them - CNN - February 1st, 2021
- CCMB team identifies variants of genes that metabolise drugs - BusinessLine - February 1st, 2021
- NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics - GlobeNewswire - February 1st, 2021
- Copy number variations linked to autism have diverse but overlapping effects - Spectrum - February 1st, 2021
- Genomes, Maps, And How They Affect You - IFLScience - February 1st, 2021
- SMART Study Finds 22q11.2 Microdeletion Prevalence Much Higher than Expected - PRNewswire - February 1st, 2021
- Are Phages Overlooked Mediators of Health and Disease? - The Scientist - February 1st, 2021
- When Your Chance for a Covid Shot Comes, Dont Worry About the Numbers - Kaiser Health News - February 1st, 2021
- Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and... - February 1st, 2021
- The First Targeted Therapy For Lung Cancer Patients With The KRAS Gene MutationExtraordinary Results With Sotorasib - SurvivorNet - February 1st, 2021
- Genetic Testing: MedlinePlus - January 29th, 2021
- 21 Common Genetic Disorders: Types, Symptoms, Causes ... - January 29th, 2021
- Genetic Counseling Online Course - School of Medicine ... - January 29th, 2021